Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Deterding

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Journal of Viral Hepatitis|November 6, 2024
Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus TreatmentMeike Dirks, Ann-Katrin Hennemann, Gerrit M Grosse, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infectionChristoph Höner zu Siederdissen, Sven Pischke, Jerome Schlue, et al.
European Journal of Immunology|June 15, 2016
Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapyJulia Hengst, Benedikt Strunz, Katja Deterding, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2015
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world settingChristoph Höner Zu Siederdissen, Benjamin Maasoumy, Katja Deterding, et al.
Journal of Hepatology|March 9, 2010
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspectiveJerzy Jaroszewicz, Beatriz Calle Serrano, Karsten Wursthorn, et al.
Antiviral Therapy|September 9, 2011
Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analoguesJerzy Jaroszewicz, Huy Ho, Antoaneta Markova, et al.
Journal of Hepatology|February 27, 2010
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analoguesJurriën G P Reijnders, Katja Deterding, Jörg Petersen, et al.
Liver Cancer|March 1, 2019
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus InfectionSolomon Owusu Sekyere, Bernhard Schlevogt, Friederike Mettke, et al.
Alimentary Pharmacology & Therapeutics|January 12, 2024
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infectionLisa Sandmann, Elisabetta Degasperi, Kerstin Port, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 5, 2015
Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasmsAndrej Potthoff, Dina Attia, Sven Pischke, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Journal of Viral Hepatitis|November 6, 2024
Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus TreatmentMeike Dirks, Ann-Katrin Hennemann, Gerrit M Grosse, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infectionChristoph Höner zu Siederdissen, Sven Pischke, Jerome Schlue, et al.
European Journal of Immunology|June 15, 2016
Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapyJulia Hengst, Benedikt Strunz, Katja Deterding, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2015
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world settingChristoph Höner Zu Siederdissen, Benjamin Maasoumy, Katja Deterding, et al.
Journal of Hepatology|March 9, 2010
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspectiveJerzy Jaroszewicz, Beatriz Calle Serrano, Karsten Wursthorn, et al.
Antiviral Therapy|September 9, 2011
Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analoguesJerzy Jaroszewicz, Huy Ho, Antoaneta Markova, et al.
Journal of Hepatology|February 27, 2010
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analoguesJurriën G P Reijnders, Katja Deterding, Jörg Petersen, et al.
Liver Cancer|March 1, 2019
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus InfectionSolomon Owusu Sekyere, Bernhard Schlevogt, Friederike Mettke, et al.
Alimentary Pharmacology & Therapeutics|January 12, 2024
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infectionLisa Sandmann, Elisabetta Degasperi, Kerstin Port, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 5, 2015
Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasmsAndrej Potthoff, Dina Attia, Sven Pischke, et al.
Pageof 10